Pfizer settles patent litigation regarding Teva's generic Neurontin

05/31/2011 | Bloomberg

Pfizer reached a settlement with Teva Pharmaceutical Industries that lets the latter continue marketing a generic version of epilepsy medicine Neurontin. Pfizer had said generic Neurontin sold by Teva and its unit Ivax, as well as Actavis Group subsidiary Purepac, infringes a key patent that lasts until 2017.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN